

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034837 A2

(51) International Patent Classification:
A61K 31/712 (2006.01) *C12N 15/11* (2006.01)

(21) International Application Number:
PCT/US2022/075715

(22) International Filing Date:
31 August 2022 (31.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/239,271 31 August 2021 (31.08.2021) US
63/341,848 13 May 2022 (13.05.2022) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **ZUBER, Jeffrey**; c/o Alnylam Pharmaceu-
ticals, Inc., 675 West Kendall Street, Henri A. Ter-
meer Square, Cambridge, Massachusetts 02142 (US).
MCININCH, James D.; c/o Alnylam Pharmaceuticals,
Inc., 675 West Kendall Street, Henri A. Termeer Square,
Cambridge, Massachusetts 02142 (US). **SCHLEGEL,**
Mark K.; c/o Alnylam Pharmaceuticals, Inc., 675 West
Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US). **CASTORENO, Adam**; c/o Al-
nylam Pharmaceuticals, Inc., 675 West Kendall Street, Hen-
ri A. Termeer Square, Cambridge, Massachusetts 02142
(US). **BONDURANT, Lucas**; c/o Alnylam Pharmaceu-
ticals, Inc., 675 West Kendall Street, Henri A. Termeer
Square, Cambridge, Massachusetts 02142 (US). **OZA,**
Dhaval; c/o Alnylam Pharmaceuticals, Inc., 675 West
Kendall Street, Henri A. Termeer Square, Cambridge,
Massachusetts 02142 (US).

(74) Agent: **MEIGS, Julie Broadus et al.**; Womble Bond
Dickinson (US) LLP, P.O. Box 570489, Atlanta, Georgia
30357-0037 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: CELL DEATH-INDUCING DFFA-LIKE EFFECTOR B (CIDEB) IRNA COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the CIDEB gene, as well as methods of inhibiting expression of CIDEB, and methods of treating subjects that would benefit from reduction in expression of CIDEB, such as subjects having a CIDEB-associated disease, disorder, or condition, using such dsRNA compositions.

WO 2023/034837 A2